Combination of IGF1R/FAK inhibition and PI3K/mTOR inhibition in triple-negative breast cancers

被引：0
|
作者：
Taliaferro-Smith, LaTonia D. [1 ]
Liu, Tongrui [1 ]
Alcaide, Tiffanie Y. [1 ]
McGlothen, Tanisha Z. [1 ]
O'Regan, Ruth M. [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P5-07-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-07-07
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer
    Zhang, Zhizhu
    Richmond, Ann
    Yan, Chi
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [42] Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition
    Herkert, Barbara
    Kauffmann, Audrey
    Molle, Sandra
    Schnell, Christian
    Ferrat, Thomas
    Voshol, Hans
    Juengert, Janina
    Erasimus, Helene
    Marszalek, Gregory
    Kazic-Legueux, Malika
    Billy, Eric
    Ruddy, David
    Stump, Mark
    Guthy, Daniel
    Ristov, Mitko
    Calkins, Keith
    Maira, Sauveur-Michel
    Sellers, William R.
    Hofmann, Francesco
    Hall, Michael N.
    Brachmann, Saskia M.
    [J]. CANCER RESEARCH, 2016, 76 (02) : 390 - 402
  • [43] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    [J]. CANCER RESEARCH, 2015, 75
  • [44] The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells
    Eskiler, Gamze Guney
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2019, 22 : 599 - 611
  • [45] PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer
    Zhang, Huan-ping
    Jiang, Rui-yuan
    Zhu, Jia-yu
    Sun, Ke-na
    Huang, Yuan
    Zhou, Huan-huan
    Zheng, Ya-bing
    Wang, Xiao-jia
    [J]. BREAST CANCER, 2024, 31 (04) : 539 - 551
  • [46] Role of piperine in chemoresistance of triple-negative breast cancer: Potential modulation of PI3K/Akt/mTOR pathway
    Fattah, Aliaa Abdel
    Zaki, Amr
    Kamel, Kohinour
    Yasser, Lidia
    Barsom, Marina
    Ahmed, MennatAllah
    Gamal, Mohamed
    Hakeem, Andrew
    El-Kersh, Dina
    Attia, Yasmeen
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2539 - 2540
  • [47] β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
    Yi, Yong Weon
    Kang, Hyo Jin
    Bae, Edward Jeong
    Oh, Seunghoon
    Seong, Yeon-Sun
    Bae, Insoo
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2015, 47 : e143 - e143
  • [48] β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
    Yong Weon Yi
    Hyo Jin Kang
    Edward Jeong Bae
    Seunghoon Oh
    Yeon-Sun Seong
    Insoo Bae
    [J]. Experimental & Molecular Medicine, 2015, 47 : e143 - e143
  • [49] Evaluation of synergistic PI3K/Akt and MEK5/ERK5 inhibition in triple-negative breast cancer
    Wright, Thomas D.
    Raybuck, Christopher
    Gartland, Nathan
    Wendekier, Katy
    Monlish, Darlene
    Chakrabarty, Suravi
    Flaherty, Patrick T.
    Burow, Matthew E.
    Cavanaugh, Jane E.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [50] PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma
    Babichev, Yael
    Kabaroff, Leah
    Datti, Alessandro
    Uehling, David
    Isaac, Methvin
    Al-awar, Rima
    Prakesch, Michael
    Sun, Ren X.
    Boutros, Paul C.
    Venier, Rosemarie
    Dickson, Brendan C.
    Gladdy, Rebecca A.
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
12345